Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMB-001
- Development stage
- Phase 4
- Lead developer
- LEO Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
TMB-001 is an investigational topical ointment formulation of isotretinoin that uses a patented polyethylene glycol (IPEG) delivery system. It was being developed for the treatment of moderate to severe congenital ichthyosis, including X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI). The formulation was designed to improve hydration and lubrication of the skin in patients with this rare genetic disorder.
- Brand names
- TMB-001TMB001TMB 001
- Other names
- Topical isotretinoin
02
Targets
RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on TMB-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMB-001.